These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29921021)

  • 41. Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis.
    Yabe M; Medeiros LJ; Wang SA; Tang G; Bueso-Ramos CE; Jorgensen JL; Bhagat G; Chen W; Li S; Young KH; Miranda RN
    Am J Surg Pathol; 2017 Jan; 41(1):82-93. PubMed ID: 27755009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma.
    Sumi M; Takeda W; Kaiume H; Kirihara T; Kurihara T; Sato K; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Kobayashi H
    Leuk Lymphoma; 2015 Apr; 56(4):1140-2. PubMed ID: 25065703
    [No Abstract]   [Full Text] [Related]  

  • 43. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T-cell gamma/delta hepatosplenic lymphoma - prolonged remission induced by aggressive first line treatment.
    Procházka V; Papajík T; Jarosová M; Pikalová Z; Indrák K; Tichý M; Kucerová L; Fakan F; Bílý M; Starostka D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):275-6. PubMed ID: 16601770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
    Kalac M; Ostojić S; Gasparov S; Planinc-Peraica A; Dominis M; Jaksić B
    Lijec Vjesn; 2006; 128(3-4):76-8. PubMed ID: 16808095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation.
    Machino T; Okoshi Y; Kaneko S; Obara N; Mukai HY; Suzukawa K; Hasegawa Y; Yamashita Y; Mori N; Kojima H; Nagasawa T
    Bone Marrow Transplant; 2007 Apr; 39(8):513-4. PubMed ID: 17310131
    [No Abstract]   [Full Text] [Related]  

  • 47. Cytotoxic hepatosplenic gammadelta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma chains of the T-cell receptor. Biologic and clinical features.
    Weidmann E; Hinz T; Klein S; Schui DK; Harder S; Kriener S; Kabelitz D; Hoelzer D; Mitrou PS
    Haematologica; 2000 Oct; 85(10):1024-31. PubMed ID: 11025592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party.
    Tanase A; Schmitz N; Stein H; Boumendil A; Finel H; Castagna L; Blaise D; Milpied N; Sucak G; Sureda A; Thomson K; Vandenberghe E; Vitek A; Dreger P;
    Leukemia; 2015 Mar; 29(3):686-8. PubMed ID: 25234166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma.
    Rashidi A; Cashen AF
    Blood Cancer J; 2015 Jun; 5(6):e318. PubMed ID: 26047388
    [No Abstract]   [Full Text] [Related]  

  • 50. [Comparison of the therapeutic effects of high-dose chemotherapy and autologous stem cell transplantation in T cell lymphoma].
    Wang Y; Wu DP; Wu XJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):298-9. PubMed ID: 20510084
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
    Thai A; Prindiville T
    J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatosplenic T-cell lymphoma and TNF-α inhibitors.
    Pozadzides JV; Pro B
    Expert Rev Hematol; 2009 Dec; 2(6):611-4. PubMed ID: 21082951
    [No Abstract]   [Full Text] [Related]  

  • 55. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases.
    Mellgren K; Attarbaschi A; Abla O; Alexander S; Bomken S; Bubanska E; Chiang A; Csóka M; Fedorova A; Kabickova E; Kapuscinska-Kemblowska L; Kobayashi R; Krenova Z; Meyer-Wentrup F; Miakova N; Pillon M; Plat G; Uyttebroeck A; Williams D; Wróbel G; Kontny U;
    Ann Hematol; 2016 Aug; 95(8):1295-305. PubMed ID: 27270301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation.
    Sakai R; Fujisawa S; Fujimaki K; Kanamori H; Ishigatsubo Y
    Bone Marrow Transplant; 2006 Mar; 37(5):537-8. PubMed ID: 16415891
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.